INTERVIEWS

Josh Douglas discusses the ongoing shift from fee-for-service to value-based care and the keys to achieving true value-based care.

In this session, Ariel can share her insights into one of the biggest mysteries of our bodies, the brain, and how tech-enabled meditation is disrupting everything we know about it. She will also take her expertise and teach the audience what it means to understand what is physically happening in your brain during meditation and the mental wellness benefits of the practice.

Vivian Owen discusses the benefits of breastfeeding to improve infant developmental and psychological health and according to the American Association of Pediatrics, reduces the risk of premenopausal breast cancer and ovarian cancer.

Walter Denton discusses his sarcoma diagnosis, Swim Across America, and how he and his family have taken a challenging situation and turned it into a family and community philanthropic effort.

Dr. Amanda Sheehan talks about Digital Smile Design, a software recently created in Brazil that allows the patient to see how their new smile can look through the use of photos, videos, and temporary mock-ups.

Gigi Sorenson, R.N., GlobalMed’s Chief Clinical Officer and Vice President of Operations,  discusses the benefits of telemedicine in pediatric care.

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses Merck’s KEYTRUDA with Inlyta as first-line treatment for advanced renal cell carcinoma.

Dr. Suela Sulo, a study author & health outcomes researcher at Abbott talks about the first-of-its-kind study published in the Journal of Parenteral and Enteral Nutrition.

Dr. Darius Francescatti, a breast surgeon with Rush University Medical Center, discusses the latest technological advances designed to enhance the effectiveness of lumpectomy procedures, including the use of 3D tomography (Kubtec’s Mozart System) in the operating room, and why the 20 percent average re-excision rate for the U.S. is too high.

Dr. Neal D. Shore discusses the FDA approval of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer.